Combining Perifosine and CCI-779 to Treat Glioblastoma
Author Information
Author(s): Pitter Kenneth L., Galbán Craig J., Galbán Stefanie, Saeed-Tehrani Omid, Li Fei, Charles Nikki, Bradbury Michelle S., Becher Oren J., Chenevert Thomas L., Rehemtulla Alnawaz, Ross Brian D., Holland Eric C., Hambardzumyan Dolores
Primary Institution: Memorial Sloan-Kettering Cancer Center
Hypothesis
How do PDGF-driven glioblastomas respond to Akt and mTOR inhibition?
Conclusion
The combination of perifosine and CCI-779 effectively inhibits the PI3K/mTOR pathway, leading to decreased tumor proliferation and increased cell death in glioblastoma models.
Supporting Evidence
- The combination treatment significantly decreased levels of pAkt and pS6RP.
- Both drugs together led to a marked increase in cell death in glioma models.
- Imaging studies showed changes in tumor cellularity corresponding to treatment response.
- PTEN status influenced the sensitivity of gliomas to mTOR inhibition.
- Statistically significant decreases in tumor proliferation were observed with combination therapy.
Takeaway
This study shows that using two drugs together can help kill brain cancer cells better than using them alone.
Methodology
The study used genetically engineered mouse models of glioblastoma to test the effects of perifosine and CCI-779 on tumor growth and signaling pathways.
Potential Biases
Potential bias in drug delivery effectiveness due to the blood-brain barrier.
Limitations
The study's findings may not be directly applicable to all glioblastoma subtypes due to the specific model used.
Participant Demographics
Mice with genetically engineered glioblastoma models.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website